research
-
VIPER aims to fast track Long COVID biomarkers. Here’s how it works.
Led by researchers at UCSF, the research program plans to validate promising candidates for noninvasive tests that can be used to advance clinical trials.
-
How to interpret clinical trial results for Long COVID
With no proven treatments or cures, many people with Long COVID are turning to off-label medications, supplements, and medical devices to treat their symptoms. There are numerous options — and some of them even have clinical trials underway or are reporting results. But even if one study suggests a treatment might work, another might contradict…
-
Experimental peptides are being advertised for Long COVID. But the evidence is trailing behind.
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.
-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say.
-
Research ethics boards need urgent training on Long COVID and myalgic encephalomyelitis
Last year, researchers in Ontario, Canada started recruiting participants for a Long COVID trial testing the feasibility of exercise and rehabilitation. Like many other studies of exercise, it doesn’t use validated measures for post-exertional malaise (PEM). But the Pursuing Reduction in Fatigue After COVID-19 via Exercise and Rehabilitation (PREFACER) study, run by researchers at Western…
-
A toolkit for new advocates: What I learned from the Long COVID Moonshot campaign
While the multi-billion dollar Long COVID Moonshot bill is currently stalled, advocates learned many important lessons that the community must carry into future efforts.
-
Breaking the vicious cycle: How two German scientists seek to solve ME
A “unifying” hypothesis of the mechanisms, triggers, and risk factors for myalgic encephalomyelitis (ME), is gaining support. Further evaluation and development of a potential drug depend on funding.
-
A test for Long COVID can’t leave anyone behind
A test for Long COVID will be transformative, and we should start preparing for its arrival now.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance